HEDRIN 4% CUTANEOUS SOLUTION
Active substance: DIMETICONE
View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT
Hedrin 4% cutaneous solution Packaging to state: Hedrin 4% lotion dimeticone
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dimeticone 4% w/w For excipients, see 6.1
3
PHARMACEUTICAL FORM
Cutaneous solution Hedrin is a clear, colourless liquid
4
4.1
CLINICAL PARTICULARS
Therapeutic indications Hedrin is indicated for the eradication of headlice infestations
4.2
Posology and method of administration Adults and children (aged six months and above) For topical external use only Apply sufficient lotion to cover dry hair from the base to the tip to ensure that no part of the scalp is left uncovered. Work into the hair spreading the liquid evenly from roots to tips. Allow hair to dry naturally. Hedrin should be left on hair for a minimum of 8 hours or overnight. Wash out with normal shampoo, rinsing thoroughly with water. Repeat the treatment after seven days. Children under the age of six months should only be treated under medical supervision.
4.3
Contraindications Hypersensitivity to any of the ingredients
4.4
Special warnings and precautions for use Discontinue at the first appearance of a skin rash or any other signs of local or general hypersensitivity. Should any signs of hypersensitivity occur (e.g. rashes, urticaria, generalised pruritus, breathing difficulties), the product
should be shampooed off immediately, and if symptoms do not resolve, medical advice sought. For external use only. Avoid contact with the eyes but if accidentally introduced into the eyes, flush with water. Consult a pharmacist if live lice are detected after the second treatment or if head lice are a persistent or recurring problem. Hedrin 4% cutaneous solution is combustible when on the hair and in direct contact with an open flame or other source of ignition; therefore during treatment hair should be kept away from open flames or other sources of ignition. The labels and leaflets will state: Warning: Keep hair away from sources of ignition, especially naked flames and burning cigarettes, whilst being treated with Hedrin. Treated hair can readily burn if ignited.
4.5
Interaction with other medicinal products and other forms of interaction Dimeticone is not known to interact with other drugs
4.6
Pregnancy and lactation There is no data to suggest that Hedrin may not be used in pregnancy
4.7
Effects on ability to drive and use machines None known
4.8
Undesirable effects Dimeticone is usually well tolerated. Minor adverse events include skin irritation, an itchy or flaky scalp and irritation around the eyes. Signs of
hypersensitivity reactions including rash, urticaria, generalised pruritus, and breathing difficulties.
4.9
Overdose There are no known recognised symptoms of overdose. It is unlikely that Hedrin lotion will enter the bloodstream via scratched skin however if this does occur, available data suggests it will be rapidly eliminated unchanged. If the lotion were to be accidentally ingested, again, the available data suggests that there are no specific safety concerns. No special procedures are likely to be needed.
5
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties The solution contains dimeticone, which is used in many pharmaceutical and cosmetic preparations. A 4% concentration has been found to affect the physico-physiological activity of lice. It is less effective in its ovicidal activity and therefore two applications 7 days apart are required. Hedrin contains no neurotoxic organophosphate insecticides and therefore does not work by acting on specific enzymes within the louse. The Hedrin solution acts on the lice by a physical process to cover the lice and disrupt the ability of the lice to manage its water balance so that treated insects fail to excrete surplus water. Hedrin activity is not diminished in insecticide resistant head lice.
5.2
Pharmacokinetic properties Hedrin is applied topically to the affected area but there is little or no absorption of Hedrin through the skin.
5.3
Preclinical safety data There are no further relevant data
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Cyclomethicone 5
6.2
Incompatibilities None known
6.3
Shelf life Three years, when stored unopened
6.4
Special precautions for storage This product does not require any special storage conditions
6.5
Nature and contents of container
HDPE dropper containers with screw caps; 50 & 100ml capacity. HDPE containers incorporating plastic trigger spray, cap and PE dip tube; 60 and 100ml capacity.
6.6
Special precautions for disposal Care should be taken as the product may cause a slip hazard if accidentally spilt onto smooth surfaces.
7
MARKETING AUTHORISATION HOLDER
Thornton & Ross Ltd Linthwaite Huddersfield HD7 5QH United Kingdom
8
MARKETING AUTHORISATION NUMBER
PL00240/0137
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
23/11/2005 / 15/06/2010
10
DATE OF REVISION OF THE TEXT
27/12/2012
Hedrin 4% cutaneous solution Packaging to state: Hedrin 4% lotion dimeticone
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dimeticone 4% w/w For excipients, see 6.1
3
PHARMACEUTICAL FORM
Cutaneous solution Hedrin is a clear, colourless liquid
4
4.1
CLINICAL PARTICULARS
Therapeutic indications Hedrin is indicated for the eradication of headlice infestations
4.2
Posology and method of administration Adults and children (aged six months and above) For topical external use only Apply sufficient lotion to cover dry hair from the base to the tip to ensure that no part of the scalp is left uncovered. Work into the hair spreading the liquid evenly from roots to tips. Allow hair to dry naturally. Hedrin should be left on hair for a minimum of 8 hours or overnight. Wash out with normal shampoo, rinsing thoroughly with water. Repeat the treatment after seven days. Children under the age of six months should only be treated under medical supervision.
4.3
Contraindications Hypersensitivity to any of the ingredients
4.4
Special warnings and precautions for use Discontinue at the first appearance of a skin rash or any other signs of local or general hypersensitivity. Should any signs of hypersensitivity occur (e.g. rashes, urticaria, generalised pruritus, breathing difficulties), the product
should be shampooed off immediately, and if symptoms do not resolve, medical advice sought. For external use only. Avoid contact with the eyes but if accidentally introduced into the eyes, flush with water. Consult a pharmacist if live lice are detected after the second treatment or if head lice are a persistent or recurring problem. Hedrin 4% cutaneous solution is combustible when on the hair and in direct contact with an open flame or other source of ignition; therefore during treatment hair should be kept away from open flames or other sources of ignition. The labels and leaflets will state: Warning: Keep hair away from sources of ignition, especially naked flames and burning cigarettes, whilst being treated with Hedrin. Treated hair can readily burn if ignited.
4.5
Interaction with other medicinal products and other forms of interaction Dimeticone is not known to interact with other drugs
4.6
Pregnancy and lactation There is no data to suggest that Hedrin may not be used in pregnancy
4.7
Effects on ability to drive and use machines None known
4.8
Undesirable effects Dimeticone is usually well tolerated. Minor adverse events include skin irritation, an itchy or flaky scalp and irritation around the eyes. Signs of
hypersensitivity reactions including rash, urticaria, generalised pruritus, and breathing difficulties.
4.9
Overdose There are no known recognised symptoms of overdose. It is unlikely that Hedrin lotion will enter the bloodstream via scratched skin however if this does occur, available data suggests it will be rapidly eliminated unchanged. If the lotion were to be accidentally ingested, again, the available data suggests that there are no specific safety concerns. No special procedures are likely to be needed.
5
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties The solution contains dimeticone, which is used in many pharmaceutical and cosmetic preparations. A 4% concentration has been found to affect the physico-physiological activity of lice. It is less effective in its ovicidal activity and therefore two applications 7 days apart are required. Hedrin contains no neurotoxic organophosphate insecticides and therefore does not work by acting on specific enzymes within the louse. The Hedrin solution acts on the lice by a physical process to cover the lice and disrupt the ability of the lice to manage its water balance so that treated insects fail to excrete surplus water. Hedrin activity is not diminished in insecticide resistant head lice.
5.2
Pharmacokinetic properties Hedrin is applied topically to the affected area but there is little or no absorption of Hedrin through the skin.
5.3
Preclinical safety data There are no further relevant data
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Cyclomethicone 5
6.2
Incompatibilities None known
6.3
Shelf life Three years, when stored unopened
6.4
Special precautions for storage This product does not require any special storage conditions
6.5
Nature and contents of container
HDPE dropper containers with screw caps; 50 & 100ml capacity. HDPE containers incorporating plastic trigger spray, cap and PE dip tube; 60 and 100ml capacity.
6.6
Special precautions for disposal Care should be taken as the product may cause a slip hazard if accidentally spilt onto smooth surfaces.
7
MARKETING AUTHORISATION HOLDER
Thornton & Ross Ltd Linthwaite Huddersfield HD7 5QH United Kingdom
8
MARKETING AUTHORISATION NUMBER
PL00240/0137
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
23/11/2005 / 15/06/2010
10
DATE OF REVISION OF THE TEXT
27/12/2012
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
